Recombinant Human BCA-1/CXCL13 #abs01117

abs01117-5ug

1-2 Weeks

138

abs01117-20ug

1-2 Weeks

344

abs01117-1mg

1-2 Weeks

3891

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in 20 mM PB, pH 7.4, 100 mM NaCl was filtered through a 0.2 μm filter and subsequently lyophilized.

Properties

aa_sequence

KSKVFLRPVP CVDPSICVSI NKKNWVIIEK RPVDNCGNGR IQDIRFIRRP FVSSEVQCSR LRTSYLKSSR KREMVLQMIW AEQPMQKCRR.

Concentration

> 97 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The amount of Recombinant HumanBCA-1/CXCL13 is determined to be less than 1 EU/μg using the LAL method. Let me provide you with information based on the original text.
According to the LAL method, the concentration of Recombinant HumanBCA-1/CXCL13 is found to be below 1 EU per microgram. This signifies that the level of contamination in the sample is extremely low.

Activity

The standard and fully biologically active substance display similar activity levels. Through an assay that employs human B cells for chemotaxis, biological activity was measured within a concentration range of 1.0-10 ng/ml.

Reconstitution

For optimal results, we suggest that you briefly centrifuge the vial before opening it to ensure that the contents settle at the bottom. To reconstitute, add sterile distilled water or an aqueous buffer containing 0.1% BSA until a concentration of 0.1-1.0 mg/mL is achieved. Once the stock solution is prepared, aliquot into working portions and store at ≤-20°C. Any further dilutions should be made using appropriate buffered solutions.

Stability & Storage

To ensure the stability of this lyophilized preparation, it is recommended to store it at 2-8 °C. However, for long-term storage, it should be kept at -20 °C, preferably desiccated. Once reconstituted, the preparation can be kept stable for up to one week at 2-8 °C. To achieve maximal stability, it is advisable to divide the reconstituted preparation into working aliquots and store them at temperatures ranging from -20 °C to -70 °C. It is important to avoid subjecting the product to repeated freeze/thaw cycles, as this could affect its stability.

Target

Accession

O43927

Gene IDs

10563

References

References

1. Legler DF, Loetscher M, Roos RS, et al. 1998. J Exp Med. 187:655-60.

2. Gunn MD, Ngo VN, Ansel KM, et al. 1998. Nature. 391:799-803.

3. Ansel KM, Harris RB, Cyster JG. 2002. Immunity. 16:67-76.

4. Ansel KM, Ngo VN, Hyman PL, et al. 2000. Nature. 406:309-14.